Abstract 106P
Background
Polyps are considered as obligate precancerous disease. Different authors consider that percent of malignization ranges from 20% in single polyps to 95% in diffuse polyposis. Current research examines the results of the early diagnosis of colon cancer by using the biomarker CDKN2A for development of molecular-biological methods of prognostication.
Methods
Investigations were carried out in 30 patients during the period 2017-2019, the study included patients with single polyps, multiple polyps, polyposis of the colon, as well as patients without a history of neither familial nor sporadic cancer. 21 patients had polyposis, in 9 single colon polyps. The men were 19 women 11. The average age of patients was 52,4 ± 3,8 years. The levels of methylation of the gene CDKN2A were determined 18 patients. The material for the isolation of DNA was a serum obtained from venous blood and and biopsy material in amount of 50 mg. DNA extraction was held according to standards. After the conversion of DNA methyl-specific PCR was held.
Results
Among 30 patients with polyps and polyposis of the colon serum gene CDKN2A methylated DNA was detected in 18 patients. In 4 patients malignization of the polyp was determined. The volume of surgical intervention in patients with malignization was the same as cancer. It patients without malignization surgical intervention was limited with resection of the intestine without lymph dessection. In 8 patients the test result was negative. We did not perform surgical intervention to these patients they were sent to dynamic observation. Thus, the diagnostic efficacy in detection colorectal cancer in early diagnosis of by means of methylated DNA of the gene CDKN2A was - 60.1%.
Conclusions
If there is a positive test for methylation of the CDKN2A-gene, the risk of colorectal cancer is considered very high and these patients underwent surgical treatment. Application of molecular biological marker CDKN2A may be an effective method in early diagnosis of malignization of polyps. This method of diagnosis requires a more in-depth study, based on a study of a larger number of observations. Further investigations of the CDKN2a gene in ulcerative colitis, Krohn's disease, Lynch syndrome, Jeghers syndrome might be continued.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
NCC of Uzbekistan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract